Interview with Thierry Teil, Managing Director, UCB Russia
When we first met, you mentioned that you assumed this position in 2009, to help UCB Russia recover from a flat spin in the wake of the financial crisis. What…
Address: Shabolovka str. 10Building 2, floor 3RUS – 119048 Moscow,Russia
Tel: +7 495 644 3322
Web: http://www.ucb.com/worldwide/Russia
UCB started operations in 1994, and after 2 partnering agreements, started local activities in 2005, further building its presence with Schwarz Pharma integration in 2007
UCB has two legal entities based in Moscow
– UCB Russia LLC
– UCB pharma Logistics LLC
Around 200 employees in 2011
UCB has representatives in the top 26 cities of Russia
In-market sales ~EURO 48 M in 2010
New legal entity: UCB Pharma Logistics
– Registred in 2010, Licenses granted, operational start in May. 2011
– Importation of UCB products in Russia and sales to distributors
– Partnership with a Russian distribution company FARMAT
Local manufacturing and packaging with Binnopharm
– Secondary packaging for a selected few products at the beginning
– Primary and secondary packaging planned
– Local manufacturing planned for later
– On-going finalization for this partnership on Local production, marketing and sales.
UCB Mature Products Continue to Improve Patients Outcome:
– Keppra :
Acknowledged worldwide as a landmark in the treatment of epilepsy, Keppra® is contributing to the wellbeing of thousands of Russian patients with epilepsy
-Xyzal and Zyrtec:
Bringing relief to patients with allergies, from allergic rhinitis to Chronic urticaria, in children and adults
-Isoket:
Leading nitrates in Russia for the treatment of angina pectoris with particularly helpful use in ambulances for Isoket ® spray
-Prostavasin:
Market leading treatment in conjunction to surgery for patients with Advanced Peripheral Obstructive Arterial disease as an alternative to amputation
All UCB Core Products in Russia: 2010-2011
UCB is becoming the Patient-Centric global biopharmaceutical leader
-Cimzia:
Fast response for predictable outcomes
-Vimpat:
When monotherapy is no longer enough
Launch in Russia in Sept 2010Already more than 300 severe epileptic patients treated
-Neupro:
24h continuous delivery by transdermal patch
Approval in Russia expected in July 2011 for Parkinson Disease
On-going launch following Phase 3 in Russia that has proven Cimzia’s benefit locallyNew treatment opportunity for patients with RA
When we first met, you mentioned that you assumed this position in 2009, to help UCB Russia recover from a flat spin in the wake of the financial crisis. What…
What were the difficulties in the CIS regions around the time of the financial crisis? Were there similarities to the situation in Russia? Yes, the situation in the CIS was…
IMEDA was founded in 2005, and today counts amongst its members 28 leading international companies in the Russian medical technology sector. What are the main goals of the association today,…
When we first met, you mentioned that you assumed this position in 2009, to help UCB Russia recover from a flat spin in the wake of the financial crisis. What…
Merck KGaA describes itself as the world’s oldest pharmaceutical and chemicals company. What is the company’s history here in Russia? The Russian subsidiary was actually incorporated over 100 years ago.…
Ipsen has recently announced the acquisition of a Russian pharmaceutical license. Even before this license, Russia was already one of the largest affiliates. of the group, as of 2010. The…
What were the difficulties in the CIS regions around the time of the financial crisis? Were there similarities to the situation in Russia? Yes, the situation in the CIS was…
You have been with Boehringer Ingelheim since the early days of your career in 1994. In the pharmaceutical sector, managers seem to jump from company to company quite often—but you…
You were the former director of RMBC, which was acquired in 2008 by the IMS. How important was this acquisition in terms of positioning the IMS on the Russian market?…
Roche is the leading company in the ONLS (high-technology reimbursement) segment of the prescription drug market, and also the top oncology company in Russia. As the General Manager of the…
You have been in Russia now for a bit less than a year, having come from the former Schering-Plough’s Hungary office to run the Russian MSD affiliate. In our conversation…
Binnopharm was established in 2006, with 100% of charter capital coming from holding company JSFC Sistema. What was the vision behind the creation of Binnopharm? The company was indeed established…
Nycomed is currently constructing a Greenfield plant in the Yaroslavl region, at an investment of 75-80Mn EUR. Last time we met in 2006, many foreign companies viewed local production as…
Celegene did not have a Russian affiliate office during Focus Reports’ initial report on Russia in 2006. What attracted Celgene’s relatively recent entrance into this market? We had external and…
See our Cookie Privacy Policy Here